Trial Profile
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacokinetics
- 11 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Aug 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 28 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.